SBFM (Sunshine Biopharma) LT-Debt-to-Total-Asset: 0.02 (As of Mar. 2026)

What is Sunshine Biopharma LT-Debt-to-Total-Asset?

Sunshine Biopharma SBFM -1.40% 34 LT-Debt-to-Total-Asset is 0.02 as of Mar. 2026. GuruFocus rates SBFM with a GF Score™ of 34/100 and a GF Value™ of $7.15 (Possible Value Trap). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Sunshine Biopharma's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.02.

Sunshine Biopharma's long-term debt to total assets ratio declined from Mar. 2025 (0.03) to Mar. 2026 (0.02). It may suggest that Sunshine Biopharma is progressively becoming less dependent on debt to grow their business.

Sunshine Biopharma (NAS:SBFM) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Sunshine Biopharma LT-Debt-to-Total-Asset Related Terms

Sunshine Biopharma LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Sunshine Biopharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunshine Biopharma LT-Debt-to-Total-Asset Chart

Sunshine Biopharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.86

0.02

Sunshine Biopharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.03	0.02	0.02	0.02	0.02

34GF Score

Sunshine Biopharma Inc SBFM

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Sunshine Biopharma LT-Debt-to-Total-Asset Calculation

Sunshine Biopharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	0.597	/	30.079
	=	0.02

Sunshine Biopharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	0.536	/	27.93
	=	0.02

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.02 mean?

Sunshine Biopharma (SBFM) has a LT-Debt-to-Total-Asset of 0.02 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Sunshine Biopharma and its competitors.

Is Sunshine Biopharma's LT-Debt-to-Total-Asset too high?

Sunshine Biopharma's current LT-Debt-to-Total-Asset is 0.02. Overall, Sunshine Biopharma has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Sunshine Biopharma's LT-Debt-to-Total-Asset compare to PRFX and CTTH?

Sunshine Biopharma's LT-Debt-to-Total-Asset of 0.02 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Sunshine Biopharma and its competitors. Sunshine Biopharma's current LT-Debt-to-Total-Asset is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Sunshine Biopharma stock overvalued right now?

Based on GuruFocus' analysis, Sunshine Biopharma (SBFM) is currently considered Possible Value Trap. The stock's GF Value™ is $7.15, compared to a current price of $2.11 — trading 70.5% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.02. Sunshine Biopharma's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Sunshine Biopharma (SBFM), the current LT-Debt-to-Total-Asset is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sunshine Biopharma (SBFM) Overvalued in 2026?

Based on GuruFocus' analysis, Sunshine Biopharma stock appears to be undervalued. The current stock price of $2.11 is trading 70.5% below its estimated GF Value™ of $7.15. GuruFocus considers Sunshine Biopharma to be Possible Value Trap.

Key valuation signals for SBFM:

LT-Debt-to-Total-Asset: 0.02
GF Value™: $7.15 vs. price of $2.11 (70.5% below fair value)
GF Score™: 34/100 with 4 warning signs

No single metric tells the full story. See the SBFM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sunshine Biopharma Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies PRFX CTTH CVSI BUDZ LVRLF INM SNOA CBIH SHPH GELS XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Address 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL, USA, 33301

Website https://www.sunshinebiopharma.com

Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.

34GF Score

Get the complete analysis for SBFM

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.11

Price

$7.15

GF Value

View SBFM Analysis

See LT-Debt-to-Total-Asset data for all stocks →